perpetuity.
All rights reserved. No reuse allowed without permission.

Surgical and percutaneous coronary revascularization in patients with 1 multivessel or left main disease; what happens beyond five years? A 2 systematic review and study level meta-analysis of randomized trials. 3 4 Francesco Formica a, MD, Daniel Hernandez-Vaquero b, MD, Domenico Tuttolomondo c, MD, 5 Alan Gallingani ^d, MD, Gurmeet Singh ^e, MD, Claudia Pattuzzi ^{a,d}, MD, Giampaolo Niccoli ^{a,d}, 6 MD, Roberto Lorusso f,g, MD, PhD and Francesco Nicolini a,d, MD, PhD. 7 8 9 ^a University of Parma, Department of Medicine and Surgery, Parma, Italy. 10 ^b Cardiac Surgery Department, Hospital Universitario Central de Asturias, Oviedo, Spain. ^c Cardiology Unit, University Hospital of Parma, Parma, Italy. 11 12 ^d Cardiac Surgery Unit, University Hospital of Parma, Parma, Italy. ^e Department of Critical Care Medicine and Division of Cardiac Surgery, Mazankowski Alberta 13 14 Heart Institute, University of Alberta, Edmonton, Canada. ^fCardio-Thoracic Department, Maastricht University Medical Centre, Heart and Vascular Centre, 15 16 Maastricht, The Netherlands. 17 ^gCardiovascular Research Institute Maastricht (CARIM), Maastricht, The Netherlands. 18 19 **Corresponding author:** 20 21 Prof. Francesco Formica, MD 22 UOC Cardiochirurgia 23 Azienda Ospedaliera Universitaria di Parma 24 Via A. Gramsci, 14 25 43126 Parma, Italy *Tel.:* +39 0521703278 26 E-mail: francescoformica.hs@gmail.com 27 28 francesco.formica@unipr.it 29 30 Conflict of interest: None declared 31 Funding: No funds were provided to perform this meta-analysis. 32 33 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Abbreviations: CABG = coronary artery bypass grafting. PCI = percutaneous coronary intervention DES = drug-eluting stent CAD = coronary artery disease LMD = left main disease MVD = multivessel disease RCT = randomized controlled trial OR = odd ratioHR = hazard ratio CI = confidence interval RMST = restricted mean survival time

All rights reserved. No reuse allowed without permission.

Abstract

62

88

91

92

93

94

- 63 Meta-analysis exploring outcomes beyond 5-years of trials comparing coronary artery bypass graft
- 64 (CABG) with percutaneous coronary intervention (PCI) utilizing drug-eluting stents in patients
- with coronary artery disease (CAD), are missing. We conducted a meta-analysis to compare very
- long-term outcomes, between the two interventions.
- Using electronic databases, we retrieved 4 trials, between January, 2010 and January, 2023. The
- primary endpoint was all-cause mortality. Kaplan-Meier curves of endpoint was reconstructed.
- 69 Comparisons were made by Cox-linear regression frailty model and by landmark analysis. A
- 70 flexible parametric model for survival analysis was used to obtain the time-dependent hazard-ratio.
- 71 A random-effect method was applied.
- 72 5180 patients were included and randomized to CABG (n=2586) or PCI with DES (n=2594).
- 73 During 10-year follow-up, PCI showed an overall higher incidence of all-cause mortality [hazard
- 74 ratio (HR) 1.19; 95% confidence interval (CI), 1.104-1.32; p=0.008)]. At landmark analysis, PCI
- showed higher risk of the endpoint within 5-years (HR 1.2; 95% CI, 1.06-1.53; p=0.008) while no
- difference was found at 5–10-year period (HR,1.03; 95%CI, 0.84-1.26; p=0.76). The time-varying
- HR analysis of PCI versus CABG was consistent with the results of the landmark analysis. There
- 78 was no long-term difference between the two interventions for myocardial infarction (MI)
- 79 (OR,1.42; 95%CI, 0.92-2.18; p=0.11), composite of all-cause mortality, stroke or MI (OR,1.07;
- 80 95%CI, 0.84-1.36; p=0.57), stroke (OR,0.97; 95%CI, 0.59-1.59; p=0.91) and cardiovascular death
- 81 (OR,1.02; 95%CI, 0.75-1.40; p=0.90), while PCI was associated with an increased risk for repeat
- 82 revascularization (OR,2.11; 95%CI, 1.58-2.81; p<0.001) and major adverse cardiac and
- erebrovascular events (OR,1.41; 95%CI, 1.13-1.75; p<0.0001). In conclusion, in patients with
- 84 CAD, there was a significantly overall higher incidence of all-cause mortality after PCI compared
- 85 to CABG beyond 5-year follow-up. Specifically, CABG is still favorable beyond 5 years and
- 86 maintains its gold standard role for the CAD treatment; PCI has an evident higher mortality during
- 87 the first 5 years and a comparable outcome beyond 5 years.
- 89 **Key words**: coronary artery bypass grafting; percutaneous coronary intervention; drug-eluting
- 90 stent; survival; meta-analysis; Long-term follow-up; extended follow-up; randomized trials.

Introduction

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

The 2018 European and 2021 American Guidelines recommended percutaneous coronary intervention (PCI) as an appropriate coronary revascularization strategy as alternative to coronary artery bypass grafting (CABG) in patients with left main disease (LMD) and multivessel disease (MVD), as well as with low-intermediate coronary complexity (1,2). These recommendations are based on 5-year follow-up results of randomized clinical trials (RCTs) comparing PCI with drugeluting stents (DES) and CABG, published during the last 10 years. However, life expectancy for a 80-year person of the general population in Europe and USA is around 9 years (3,4). Therefore, 5 years results are clearly not enough to decide the best strategy for the vast majority of patients. Recent meta-analyses of RCTs comparing PCI with DES and CABG in patient with LMD and or MVD, have reported conflicting results between the two interventions in terms of 5-year overall survival, stroke, myocardial infarction (MI) and repeat revascularization, although most of pooled results showed an advantage in favour of CABG over PCI (5-7). However, the choice of the optimal mode of revascularization remains controversial especially for many patients that have a life expectancy of more than 10 years. End-points of many RCTs are limited at 5 years of follow-up. But survival curves of these RCTs frequently provide longer information. This information is not usually useful in individual studies due to low statistical power after 5 years because of deaths and censored events. However, this low statistical power could be overcome by pooled analysis, which is one of the aims of the metaanalysis (8). Therefore, given the importance of the optimal revascularization strategy is still under debate, and considering that there are no meta-analyses of RCTs exploring the results of PCI with DES and CABG beyond 5 years, we conducted a comprehensive systematic review and meta-analysis with the aim of comparing very long-term outcomes, beyond 5-years, between the two interventions.

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

Methods As the aggregated data were extracted from the published articles included in the analysis, this meta-analysis is exempted from Ethical Committee (EC) evaluation as the investigators of each trial obtained the approval from the local Ethical Committees (EC). The meta-analysis adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (9) and the study protocol was registered and published online in PROSPERO (The International Prospective Register of Systematic Reviews; ID: CRD42023401293). Search strategy The search strategy consisted of a comprehensive review of relevant studies published between January 1, 2010 and January 31, 2023 in three electronic databases, PubMed, Cochrane Central Register of Controlled Trials (CENTRAL) and EMBASE. The references list of previous metaanalyses and relevant articles were also used to complete the search. Using Boolean operators ("AND" or "OR"), the search strings included ('multivessel coronary artery disease') AND ('left main disease' OR 'left main coronary artery disease') AND ('coronary artery bypass' OR 'CABG') AND ('percutaneous coronary intervention' OR 'PCI') AND ('drugeluting stents' OR 'DES' OR stenting) AND ('randomized' OR 'randomised' OR 'trials') AND ('long-term follow-up' OR 'extended follow-up'). A medical librarian refined the literature search. The search algorithm is reported in Supplementary Material (Table S1). **Inclusion criteria** Study eligibility criteria followed the PICOS format (Population; Intervention; Comparison; Outcomes; Studies). Population: patients with CAD affected by LMD and or MVD and deemed eligible for either CABG or PCI; Intervention: PCI; Comparison: CABG operation; Outcomes: overall survival and incidence of stroke, MI and repeat revascularization at longest follow-up; Studies: only RCTs written in English languages that reported graphed Kaplan-Meier (KM)

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

curves of very long-term survival (beyond 5-year follow-up) of the outcomes of interest. Two authors (DT, CP) independently scanned and reviewed titles and abstracts and disagreement was resolved by a senior author (FF). Data extraction and collection Two authors (AG, DT) independently extracted data from main text and supplementary materials of the RCTs included in the analysis. Data were then collected in a standard table sheet database (Microsoft Office Excel 2016, Microsoft, Redmond, WA, USA). The included trials were listed by first author, study period and year of publication, preoperative characteristics and postoperative outcomes. Disagreement was solved by a senior author (FF). Risk of bias assessment Two authors (NF, FF) assessed the quality of the studies and the risk of bias using the Cochrane Collaboration revised tool for randomized control trials (RoB 2) (9) (Supplementary Table S2). **Endpoints** The primary endpoint was the incidence of all-cause mortality. The secondary endpoints were repeat coronary revascularization, myocardial infarction (MI), incidence of cardiovascular (CV) death, stroke, composite outcomes (all-cause mortality, stroke and MI) and the incidence of major adverse cardiac and cerebrovascular events (MACCE) including all-cause mortality, stroke, MI and repeat coronary revascularization. Statistical analysis Data pooling and meta-analysis.

Continuous variables were reported as mean ± standard deviation (SD). Variables expressed in median and interquartile ranges were converted into mean and SD using a validated formula (11). Categorical variables were reported as number and percentages.

Primary endpoint was analyzed with two-stage approach to conduct the individual patient data (IPD) reconstruction meta-analysis (12). Secondary outcomes were compared using odd ratio (OR) and 95% confidence interval (CI) and effect estimates were calculated according to the random-effect model and the DerSimonian-Laird method and were represented with the forest plot. An OR > 1 indicated an advantage of CABG arm over PCI. Heterogeneity was evaluated with chi-squared and I² tests and defined as absent or low for I² ranging from 0% to 25%, moderate for I² ranging from 26% to 50% and high for I² above 50% (13).

Individual patient data reconstruction.

To assess the entire follow-up duration of each trial we performed an IPD analysis applying an iterative approach to reconstruct the original database of each trial using the method described by Wei, Royston et al. (14,15). We employed a dedicated software (GetData Graph Digitizer version 2.5.3; http://getdata-graph-digitizer.com) to digitize the K-M curves by importing the time (abscissa-x) and survival probability (ordinate-y) values from the original K-M curves. The databases were reconstructed by combining the extracted value of time and survival with the patients at risk for the time points indicated in the original K-M curve. Quality assessment of the databases were performed by visually comparing the K-M curves and the estimated patients at risk from the reconstructed databases with the original ones. Then, we merged data of reconstructed databases in a single database to recalculate the aggregated survival curves and the life tables. By doing this, we simulated a patient-level meta-analysis (16).

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

First stage of two-stage approach meta-analysis. Cox proportional hazards models with inclusion of frailty term to account for heterogeneity amongst trials was used to compare the two arms and the hazard ratio (HR) with 95% CIs were calculated and reported. The proportional of hazard assumption (PHA) was assessed for the primary endpoint and was tested by visual inspection of K-M curves, log-minus-log plots, predicted versus observed survival curves and the scaled Schoenfeld residuals. A p<0.05 indicated a violation of proportionality. Given the potential different long-term (0-5 years) and very long-term risks (5-10 years) of the two revascularization approaches, landmark analysis with a 5-years cut-off was planned in the statistical analysis and performed. Further, a flexible parametric model for survival analysis was used to obtain the time-dependent HRs (Royston-Parmar models) using a restricted cubic spline function. The baseline cumulative hazard was modeled using spline with 5 degrees of freedom (df; 4 intermediate knots and two knots at each boundary); the time-varying effect of intervention was modelled using a restricted cubic spline with 3 df (2 internal knots). Second stage of two-stage meta-analysis In the second stage we assessed the treatment effect estimate at longest available follow-up as OR with its 95% CI. An OR > 1 indicated an advantage of CABG arm. Effect measure was calculated according to the random-effect model and the DerSimonian-Laird method and was represented with the forest plot. Heterogeneity was evaluated with chi-squared and I² tests and defined as early described (13). Sensitivity analysis As a sensitivity analysis, we compared the pooled HRs and 95% CIs of both one-stage and twostage analysis and then, to increase the accuracy of our results, we performed an extra sensitivity

analysis according to the leave-one-out method (17) to identify the influence of a single study on the primary outcome, if heterogeneity was significant.

Restricted mean survival time

We used the restricted mean survival time (RMST) method to compare the mean survival time between CABG and PCI at a specified truncation time (t^*). The RMST represents a measure of life expectancy between the time of intervention and the t^* and was calculated as the area under the survival curve for each arm. We selected $t^* = 5$ -years, $t^* = 8$ -years and $t^* = 10$ -years for the following reasons: first, all trials have follow-up longer than 5 years; second, recent meta-analyses reported survival results at 5-years follow-up; third, the 8-years was the longest follow-up shared by the four trials; last, 10 years was the longest follow-up available. We calculated the difference of RMST between CABG and PCI (rmstD = rmstCABG - rmstPCI), which is interpretable as the number of life-years gained with PCI compared to CABG (18,19).

Tex). A two-tailed p-value < 0.05 indicated statistical significance.

Results

The literature search identified 475 records and 13 studies were considered relevant and then retrieved. Among them, 4 RCTs [BEST (NCT05125367 and NCT00997828) FREEDOM (NCT00086450), PRECOMBAT (NCT03871127 and NCT00422968) and SYNTAX (NCT03417050) (20-23)] met the eligibility criteria and were included in the final analysis. The PRISMA Flow Chart of study selection is shown in Supplemental Figure 1. The trials included 5180 patients, including 2586 patients randomized to CABG and 2594 patients to PCI with DES. All trials presented follow-up beyond 5-years with a mean weighted follow-up duration of 10.23 years. Specifically, BEST, PRECOMBAT and SYNTAX trials have reported 10-year follow-up for all-cause mortality, while FREEDOM trial has reported 8-year follow-up. In addition,

FREEDOM trial reported separately survival analysis of whole cohort (n=1900) and of extended cohort (n=943). Baseline variables of patients enrolled in each trial are reported in Table 1. Baseline characteristics of single trials are showed in Table 2. The endpoint definition of single trials is presented in supplementary material (Table S3).

Primary endpoints

All-cause mortality

The Cox linear regression frailty model revealed that PCI was associated with a higher rate of all-	-
cause mortality compared to CABG (HR 1.19; 95% CI, 1.04-1.32; p = 0.008, frailty theta 0.08))
(Fig. 1A). The PHA was not violated (p=0.4). Additional log-minus-log survival curves, predicted	-
versus-observed survival functions and the scaled Schoenfeld residuals plot are provided in the	е
supplemental materials (Fig S2 to S4). The landmark analysis showed a greater risk of adverse	e
event for PCI compared to CABG at 0-5-year period (HR 1.2; 95% CI, 1.06-1.53; p = 0.008)	,
while no difference was found at 5–10-year period (HR 1.03; 95% CI, 0.84-1.26; $p = 0.76$) (Fig.	,•
1B). We observed a statistically significant 5-year RMST difference of 0.07 years (25 days) (95%)	ó
CI, 0.01-0.125; p=0.02) gained with CABG. After 8 years of follow-up, the RMST difference was	S
statistically significant at 0.14 years (1.7 months) (95% CI, 0.03-0.25; p=0.009) gained with	1
CABG. The 10-year RMST difference was statistically significant at 0.20 years (95% CI, 0.05	-
0.35; p=0.007), suggesting a prolonged life expectancy by 0.20 years (2.4 months) in patients with	1
CABG, compared to patients with PCI (Fig. 1A and supplementary Table S4).	
The time-varying HR analysis of PCI versus CABG was consistent with the results of the landmark	ζ.
analysis (Fig. 1C). PCI and CABG showed comparable results in the first year after surgery	•
Thereafter, the benefit of CABG became clearly superior to PCI until about 6 years. Beyond 6	-
years the benefit of CABG was lost and the two interventions were comparable. In the cumulative	e
two-stage meta-analysis, the point estimate for all-cause mortality at the longest follow-up showed	f

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

a higher risk of death for PCI compared with CABG (OR 1.24, 95% CI, 1.06–1.45; p = 0.01) with low heterogeneity ($I^2=14.37\%$) (Fig. 2). We performed both first-stage and second-stage analysis of two-stage approach analysis including data of extended follow-up FREEDOM trial. Results of the Cox regression linear frailty model (HR 1.16; 95% CI, 1.01-1.32; p = 0.03, frailty theta 0.08) and the cumulative meta-analysis (OR 1.23; 95% CI, 1.06-1.42; p = 0.01) were consistent with the main analysys. **Secondary endpoints** Myocardial infarction Data on MI beyond 5-year follow-up were reported in BEST, FREEDOM and PRECOMBAT trials. In the FREEDOM trial, data on MI were recorded in 415 patients. The overall effect for MI showed that PCI and CABG were comparable (OR 1.42; 95% CI, 0.92-2.18; p=0.11) with no statistical heterogeneity (I²=0%) (Fig. 3A). Repeat coronary revascularization BEST and PRECOMBAT trials reported data for repeat coronary revascularization. The overall effect measure analysis showed that PCI was associated with a higher risk of repeat coronary revascularization (OR 2.11; 95% CI, 1.58-2.81; p<0.001) with no statistical heterogeneity (I²=0%) (Fig. 3B). Both trials reported the K-M curves. The time-to-event reconstructed curves with Cox linear regression are presented in supplementary material (Fig. S5). Composite of all-cause mortality, stroke or MI BEST and PRECOMBAT trials reported data for composite of all-cause mortality, stroke or MI. The overall effect measure analysis showed that PCI and CABG were comparable at longest follow-up (OR 1.07; 95% CI, 0.84-1.36; p=0.57) with no evidence of heterogeneity ($I^2=0\%$) (Fig.

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

3C). Both trials reported K-M curves for this composite outcome. The time-to-event reconstructed curves with Cox linear regression are presented in supplementary material (Fig. S6). Stroke Data on stroke beyond 5-year follow-up were reported in BEST, FREEDOM and PRECOMBAT trials. In the FREEDOM trial, data were recorded in 415 patients. The rate of stroke was comparable between the two interventions (OR 0.97; 95% CI, 0.59-1.59; p=0.91) without heterogeneity (I²=0%) (Fig. 3D). Cardiovascular death BEST and PRECOMBAT trials reported data for CV death. The overall effect measure analysis showed that PCI and CABG were comparable (OR 1.02; 95% CI, 0.75-1.40; p=0.90) with no heterogeneity (I²=0%) (Fig. 3E). **MACCE** BEST and PRECOMBAT trials reported data for MACCE. The PCI was associated with a higher rate of MACCE compared to CABG at available longest follow-up (OR 1.41; 95% CI, 1.13-1.75; p<0.0001) with no evidence of heterogeneity ($I^2=0\%$) (Fig. 3F). **Discussion** The principal finding of this IPD study-level meta-analysis of RCTs is that, at a longest available 10-year follow-up, there was a significant greater risk of overall mortality after PCI. We estimated a 13.3% vs. 10.2% incidence of death after the first 5-years of PCI and CABG, respectively, and at 10-years the incidence of death was still higher in PCI (23.7% and 20.5%, respectively). However, this benefit was evident in the first 6-year follow-up; after this time, risk of death was similar between both interventions. We found that, at 10-year follow-up, patients undergoing

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

surgery live longer and therefore CABG is the gold standard approach. However, this recommendation may not be as robust for younger patients or those with a longer life expectancy, because the benefit of CABG seems to be lost after 6 years of follow-up. At this point, survival curves stop diverging and become parallel. Therefore, for many patients, the decision between CABG or PCI should not be based on life expectancy, but on frailty or other considerations. Overall, we estimated a 2.4 months total gain in life expectancy in patients treated with CABG, compared to patients treated with PCI, indicating a favorable outcome of CABG. Interestingly, we also observed a progressively longer life expectancy in CABG compared with PCI, as revealed by analysis of RMST at 5, 8 and 10 years. As previous IPD meta-analyses of RCTs (5,6,24) have already reported heterogeneous results of 5-year overall mortality in patients with LMD and/or MVD treated with CABG or PCI with DES, we thought it would be interesting to perform the landmark analysis at a cut-off time of 5 years, although the PHA not being violated. Interestingly, the incidence of all-cause mortality was significantly greater with PCI at the 0-5-year interval, while no difference was observed at the 5-10-year interval. The reasons for these different scenarios are multifactorial. One explanation could be related to the follow-up available in the FREEDOM trial, which reported data of 8-year follow-up including patients from only 25 of the 141 participating centers that agreed to participate in the extended follow-up study. Another explanation could be related to the CV-related death outcome that might be challenging to define even in RCTs, and therefore it could be plausible that CV death was not assigned appropriately in both interventions. Several factors, including the extensive use of multiple arterial grafts (MAG) and performing graft anastomosis distal to the coronary stenosis, are associated with the significant reduction in mortality incidence in long-term follow-up. Several studies have reported a very high late survival rate (beyond 10-years) in patients who underwent CABG with MAG and these findings should be considered in Heart Team discussions (25-29). At the same time, advances in DES technology and

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

increased adherence to dual antiplatelet therapy could really help to increasingly reduce the incidence of mortality and complications after PCI (30,31). To the best of our knowledge, this study represents the first study-level IPD meta-analysis of RCTs focusing on follow-up beyond 5-years and has important clinical implications. Firstly, it includes trials with follow-up longer than 5-years and some previously unreported data. Secondly, we performed a reconstructed IPD meta-analyses curve to generate aggregated Kaplan-Meier plots and perform landmark analyses of primary endpoint. This allowed assessment of the entire followup duration of each RCT, and to calculate the overall RMST of primary endpoint for each intervention. Based on the available data extracted to analyze the secondary endpoints at longest follow-up, the principal findings include a comparable incidence of MI, stroke, CV death and composite of death, MI or stroke. Interestingly, incidence of repeat coronary revascularization and MACCE were higher in PCI. Analysis of secondary endpoints is of great interest to guide Heart-Teams in making the most appropriate choice between one of the two revascularization interventions in those clinical scenarios where patients present with CAD potentially treatable with CABG or PCI. In such situations, the choice of one treatment over the other should also be guided by long-term data on the incidence of stroke, MI, repeat revascularization, and CV death. Unfortunately, the paucity of such data and the different definitions of the related outcomes adopted in the protocol of the included studies, did not permit to standardize the endpoints and have more complete and confident long-term results. Of note, the all-cause mortality primary outcome has an undeniable and identical definition in all trials, while the other outcomes may also suffer from a bias in event measure. For instance, data on secondary endpoints were reported extensively in BEST and PRECOMBAT trials, while FREEDOM trial reported a paucity data regarding the incidence of stroke and myocardial infarction. Therefore, we recognize that results of secondary endpoints of this meta-analysis should be considered with caution.

This meta-analysis has several strengths and limitations to be highlighted. As strengths, this is the first meta-analysis on this topic beyond 5-years follow-up. We reconstructed the databases and simulated a patient-level meta-analysis. This allowed us to graph the survival curves of the merged studies and accurately analyze the risks at certain cut-off points. Sample size beyond 5-years was more than 3700 patients. As limitations, firstly, all trials in the analysis had different inclusion and exclusion criteria; therefore, many patients were not included in the randomization according to the decision of the Heart Team of each trial. This might explain why patients with SYNTAX score > 33 were poorly represented in all trials. Secondly, individual trial reported different endpoint definition. While all-cause mortality is an unbiased measure outcome in all included trial, the other outcomes of interest were reported heterogeneously. Finally, the trials occurred in a period of more than 10 years and different DES technology and generations were used.

Conclusion

In conclusion, in patients with LMD and or MVD there was a significantly overall higher incidence of all-cause mortality after PCI compared to CABG beyond 5-year follow-up. Specifically, CABG is still favorable beyond 5 years and maintains its gold standard role for the CAD treatment; PCI has an evident higher mortality during the first 5 years and a comparable outcome beyond 5 years. These results may help the Heart Team to tailor revascularization treatment and strategies for patients with LMD and MVD, favoring CABG for young patients and those with a life expectancy of at least 10 years, taking also into account that at 10 years after intervention, the life expectancy of CABG patients is significantly longer than that of PCI subjects by 2.4 months.

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

Role of funding source This meta-analysis was performed without funding. Acknowledgement The authors wish to thank Giorgia Pavan for her tireless contribution in English revision of the manuscript and Evelina Ceccato (medical librarian at University of Parma, Italy) for her precious support in literature search. **Data Availability Statement** The data collection forms, data extracted from included studies and all other data and materials used in this meta-analysis will be available and sharable on specific and reasonable request to the corresponding author. Conflict of interest: none declared Legends Figure 1. (B) Kaplan–Meier incidence function plot of reconstructed individual patient data analysis for all-cause mortality following coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI) and 10-year restricted mean survival time (RMST). (B) Landmark analysis for all-cause mortality following CABG or PCI. (C) Hazard ratio trend over time for all-cause CABG versus PCI estimated by fully parametric model for survival analysis. HR, hazard ratio; OR, odd ratio; CI, confidence interval. Figure 2. (A) Overall effect for all-cause mortality at longest follow-up following coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI). *OR*, *odd ratio*; *CI*, *confidence interval*;

Figure 3. (A) Overall effect for myocardial infarction at longest follow-up following coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI). (B). Overall effect for repeat coronary revascularization at longest follow-up following CABG or PCI. (C) Overall effect for composite of all-cause mortality, myocardial infarction or stroke at longest follow-up following CABG or PCI. (D) Overall effect for stoke at longest follow-up following CABG or PCI. (E) Overall effect for cardiovascular death at longest follow-up following CABG or PCI. (F) Overall effect for major adverse and cerebrovascular event (MACCE) at longest follow-up following CABG or PCI. OR, odd ratio; CI, confidence interval;

446 Table 1. Baseline variables of enrolled patients.

		BEST			FREEDOM ^a				PRECO	MBAT			SYN	TAX		
	PC	I	CAB	BG	PC	CI	CAE	BG	PC:	I	CAB	G	PC	1	CAB	3G
No. of patients	438	3	442	2	475/	953	482/9	947	300)	300	ı	903		897	
	Mean or no.	SD or %	Mean or no.	SD or %	Mean or no.	SD or %	Mean or no.	SD or %	Mean or no.	SD or %	Mean or no.	SD or %	Mean or no.	SD or %	Mean or no.	SD or %
Age	64	9,3	64,9	9,4	62,9	9,3	63,1	9,4	61,8	10	62,7	9,5	65,2	9,7	65	9,8
Male sex	304	69,4	325	73,5	361	76	344	71,4	228	76	231	77	690	76,4	708	78,9
BMI	24,7	2,9	25	2,9	29,7	5,2	29,9	5,4	24,6	2,7	24,5	3	28,1	4,8	27,9	4,5
Medical diabetes																
Any	177	40,4	186	42,1	953	100	947	100	102	34	90	30	231	25,6	221	24,6
Requiring Insuline	20	84,6	18	4,1	322	33,8	293	947	10	3,3	9	3	89	9,9	93	10,4
Hypertension	296	67,6	295	66,7	411	86,5	407	84,4	163	54,3	154	51,3	630	69,8	574	64
Hyperlipidemia	239	54,6	222	50,2					127	4,3	120	40	711	78,7	692	77,2
Smoker (current)	88	20,1	89	20,1	80	16,8	82	17	89	29,7	83	27,7	167	18,5	197	22
Previous PCI	30	6,8	38	8,6					38	12,7	38	12,7				
Previous MI	25	5,7	29	6,6	109	22,9	96	19,9	13	4,3	20	6,7	288	31,9	303	33,8
Previous CHF	16	3,7	12	2,7					0	0	2	0,7	36	4	47	5,3
Previous stroke	37	8,4	33	7,5	25	5,7	21	4,4				·	35	3,9	43	4,8
Chronic Renal failure	9	2,1	7	1,6					4	1,3	1	0,3				.,,
PVD	15	3,4	12	2,7					15	5	7	2,3	73	8,1	75	8,4
COPD	8	1,8	6	1,4					6	2	10	3,3				
Clinical presentation												-				
Stable angina	210	47,9	204	46,2			-		160	53,3	137	45,7	514	56,9	513	57,2
Unstable angina	185	42,2	199	45					128	42,7	144	48	261	28,9	251	28

										•						
AMI (<90 days)	43	9,8	39	8,8												
Recent MI (within 7 days of random)																
Recent acute coronary syndrome					161	33,9	152	31,5				-				
Unstable angina and recent NSTEMI									12	4	19	6,3				
EF	59,1	8,5	59,9	8,1	65,7	12,1	66,6	10,5	61,7	8,3	60,6	8,5	1			
N of diseased vessels																
3	330	75,3	349	79	394/474	83,1	414/480	86,3	122	40,7	123	41	546	60	549	61
2	108	24,7	93	21					101	33,7	90	30				
EuroSCORE																
mean score	2,9	2	3	2,1	2,8	2,7	2,8	2,8	2,6	1,8	2,8	1,9	2,8	2,6	3,8	2,7
median					2.0	(1,3- 3,2)	2,1	(1,3- 3,3)				-				
SYNTAX score																
mean score	24,2	7,5	24,6	8,1	26,9	8,2	26,1	8,1	24,3	9,6	25,3	10,9	28,4	11,5	29,1	11,4
median					27	(21- 31,5)	26	(20-31)								
>=33	66	15,1	79	17,9	98	20,6	92/479	19,2	58	19,3	68	22,7	290	32,1	315	35,1
22-32	187	42,7	177	40,0	228	48	220/479	45,9	102	34,0	97	32,3	310	34,3	300	33,4
<=22	185	42,2	186	42,5	149	31,4	167/479	34,9	129	43,0	104	34,7	299	33,1	275	30,7

a) FREEDOM trial data refer to whole cohort; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; BMI, body mass index; MI; myocardial infarction; CHF, congestive heart failure; PVD, peripheral vascular disease; COPD; chronic obstructive pulmonary disease; EF, ejection fraction.

Table 2. Baseline characteristics of trials included in the meta-analysis

Study acronym -	Study	Study	Total	CABG	PCI-	Entry criteria	Stent Type	Primary outcome	Secondary	Follow-up
year	period	design	patients		DES				outcomes	(median)
FREEDOM (NCT00086450) 2019	April 2005 - April 2010	Multicenter 25/141 sites	1900	947	953	≥70% stenosis 2 or 3 vessel CAD Only diabetes No LM disease	Sirolimus - eluting and paclitaxel- eluting stents	Composite of death from any cause, nonfatal myocardial infarction and nonfatal stroke	Major adverse cardiovascular and cerebrovascular events 30 days and 12 months after the procedure (including components of the primary outcome as well as repeat revascularization) and annual all-cause and cardiovascular mortality.	7,5 (IQR 5 to 9)
SYNTAX (NCT03417050) 2019	March 2005 - April 2007	Multicenter 85 sites	1800	897	903	≥70% stenosis 2 or 3 vessel CAD and ≥50% LMCA visual stenosis. Silent ischemia or stable/unstable angina.	Paclitaxel- eluting	Composite rate of MACCE at 1 year, defined as all-cause mortality, stroke, myocardial infarction, and repeat revascularisation.	MACCE rates at 1 month, 6 months, 3 years, and 5 years, rates of the individual MACCE components; rates of stent thrombosis or graft occlusion.	11.2 (IQR 7.7-12.1)
PRECOMBAT (NCT03871127 and NCT00422968) 2021	April 2004 -Agoust 2009	Multicenter 13 sites	600	300	300	Unprotected left main coronary artery (ULMCA) stenosis (>50% by visual estimation) with or without any additional target lesions	Sirolimus- eluting	Composite of all- cause mortality, MI, stroke or ischaemia-driven revascularisation at 1-year follow- up	Individual components of the primary endpoint; composite of death, MI, or stroke; and clinically driven revascularization	11,3 (IQR 10,2-13)

						(>70% by visual estimation).				
BEST (NCT05125367 and NCT00997828) 2022	July 2008 - September 2013	Multicenter 27 sites	1776	442	438	CAD 2 or 3 vessel disease - no LMD; stenosis > 70%; indication for revascularization based on symptoms of angina or evidence of myocardial ischemic	Everolimus- eluting	Composite of death, myocardial infarction or target-vessel revascularization at 5 years follow-up	Composite of death, myocardial infarction, or stroke and a composite of death, myocardial infarction, stroke, or any repeat revascularization. Individual components of the composite endpoints; stent thrombosis and major or fatal bleeding.	11,8 (IQR 10,6-12,5)

PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; CAD, coronary artery disease; DES, drug-eluting stent; LMD, left main disease.




Fig. 1A




Fig. 1B





Fig. 1C

All rights reserved. No reuse allowed without permission.

Odd ratio for all-cause mortality at longest follow-up



487

488

490

491

492

493

494

495

496

497

498

489 Fig. 2

Odd ratio for spontaneous myocardial infarction at longest follow-up





Fig. 3A

Odd ratio for repeat coronary revascularization at longest follow-up



Random-effects DerSimonian-Laird model

499

500

501

502

503

504

505

506

507

508

509

Fig. 3B

Odd ratio for composite of any death, myocardial infarction or stroke at longest follow-up




Fig. 3C




Fig. 3D




Fig. 3E

Odd ratio for MACCE at longest follow-up PCI **CABG** OR Weight with 95% CI Study No Yes No (%) Yes 1.29 [0.90, 1.86] 35.76 PRECOMBAT 2021 87 213 72 228 **BEST 2022** 1.47 [1.12, 1.93] 64.24 194 244 155 287 Overall 1.41 [1.13, 1.75] Heterogeneity: $\tau^2 = 0.00$, $I^2 = 0.00\%$, $H^2 = 1.00$ Test of overall effect: z = 3.07, p < 0.00012.00 1.00 1.50 Favor PCI

Favor CABG

Random-effects DerSimonian-Laird model

519

520

522

523

524

525

526

527

528

529

530

531

532

533

534

535

536

537

538

539

Fig. 3F 521

541

542

543

544

545

546

547

548

549

550

551

552

553

554

555

556

557

558

559

560

561

562

563

564

References 1) Neumann FJ, Sousa-Uva M, Ahlsson A, et al.; ESC Scientific Document Group. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019;40:87-165. 2) Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022;79:197-215. 3) https://ec.europa.eu/eurostat/web/products-eurostat-news/-/EDN-20170930-1 (last access 3d, March 2023) 4) https://www.ssa.gov/oact/STATS/table4c6.html (last access 3d, March 2023) 5) Sabatine MS, Bergmark BA, Murphy SA, et al. Percutaneous coronary intervention with drug-eluting stents versus coronary artery bypass grafting in left main coronary artery disease: an individual patient data meta-analysis. Lancet. 2021;398:2247-2257. 6) Head SJ, Milojevic M, Daemen J, et al. Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data. Lancet. 2018;391:939-948. 7) Gaudino M, Hameed I, Farkouh ME, et al. Overall and Cause-Specific Mortality in Randomized Clinical Trials Comparing Percutaneous Interventions With Coronary Bypass Surgery: A Meta-analysis. JAMA Intern Med. 2020;180:1638-1646. 8) Deeks JJ, Higgins JPT, Altman DG. Chapter 10: Analysing data and undertaking metaanalyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA. Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022.

565 9) Moher D, Liberati A, Tetzlaff J, et al; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. Open Med. 2009;3:e123-566 30. 567 568 10) Stene JAC, Savovic J, Page MJ, et al. RoB2: a revised tool for assessing risk if bias in randomized trials. BMJ 2019;366:I4898. 569 570 11) Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005;5:13. 571 12) Richard D. Riley, Thomas P.A. Debray, Tim P. Morris, and Dan Jackson. The Two-stage 572 Approach to IPD Meta-Analysis. 573 13) Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 574 2002;21:1539–58. 575 576 14) Wei Y, Royston P. Reconstructing time-to-event data from published Kaplan-Meier 577 curves. Stata J. 2017;17:786-802. 15) Liu N, Zhou Y, Lee JJ. IPD from KM: reconstruct individual patient data from published 578 579 Kaplan-Meier survival curves. BMC Med ResMethodol. 2021;21:111. 16) Diaz R, Hernandez-Vaguero D, Alvarez-Cabo R, Avanzas P, Silva J, Moris C, Pascual I. 580 Long-term outcomes of mechanical versus biological aortic valve prosthesis: Systematic 581 review and meta-analysis. J Thorac Cardiovasc Surg. 2019 Sep;158(3):706-714). 582 17) Viechtbauer W, Cheung MW. Outlier and influence diagnostics for meta-analysis. Res 583 Synth Methods. 2010;1:112-25. 584 18) Wei Y, Royston P, Tierney JF, et al. Meta-analysis of time-to-event outcomes from 585 586 randomized trials using restricted mean survival time: application to individual participant 587 data. Stat Med. 2015;34:2881-2898. 588 19) Royston P, Parmar MK. Restricted mean survival time: an alternative to the hazard ratio 589 for the design and analysis of randomized trials with a time-to-event outcome. BMC Med 590 Res Methodol. 2013;13:152.

592

593

594

595

596

597

598

599

600

601

602

603

604

605

606

607

608

609

610

611

612

613

614

615

20) Ahn JM, Kang DY, Yun SC, Ho Hur S, Park HJ, Tresukosol D, et al. Everolimus-Eluting Stents or Bypass Surgery for Multivessel Coronary Artery Disease: Extended Follow-Up Multicenter Randomized Controlled Outcomes of **BEST** Trial. Circulation. 2022;146:1581-1590. 21) Farkouh ME, Domanski M, Dangas GD, Godoy LC, Mack MJ, Siami FS, et al; FREEDOM Follow-On Study Investigators. Long-Term Survival Following Multivessel Revascularization in Patients With Diabetes: The FREEDOM Follow-On Study. J Am Coll Cardiol. 2019;73:629-638. 22) Jeong YJ, Ahn JM, Hyun J, Lee J, Kim JH, Yang Y, et al. Ten-year Outcomes After Drug-Eluting Stents or Bypass Surgery for Left Main Coronary Disease in Patients With and Without Diabetes Mellitus: The PRECOMBAT Extended Follow-Up Study. J Am Heart Assoc. 2021;10:e019834. 23) Thuijs DJFM, Kappetein AP, Serruys PW, Mohr FW, Morice MC, Mack MJ, et al. SYNTAX Extended Survival Investigators. Percutaneous coronary intervention versus coronary artery bypass grafting in patients with three-vessel or left main coronary artery disease: 10-year follow-up of the multicentre randomised controlled SYNTAX trial. Lancet. 2019;394:1325-1334. 24) Ahmad Y, Howard JP, Arnold AD, et al. Mortality after drug-eluting stents vs. coronary artery bypass grafting for left main coronary artery disease: a meta-analysis of randomized controlled trials. Eur Heart J. 2020;41:3228-3235. 25) Thuijs DJFM, Davierwala P, Milojevic M, eta 1; SYNTAX Extended Survival Investigators. Long-term survival after coronary bypass surgery with multiple versus single arterial grafts. Eur J Cardiothorac Surg. 2022;61:925-933. 26) Taggart DP, Gaudino MF, Gerry S, et al.; ART investigators. Effect of total arterial grafting in the Arterial Revascularization Trial. J Thorac Cardiovasc Surg. 2022;163:1002-1009.e6.

27) Formica F, Maestri F, D'Alessandro S, et al. Survival effect of radial artery usage in addition to bilateral internal thoracic arterial grafting: A meta-analysis. J Thorac Cardiovasc Surg. 2021 Epub ahead of print. 28) Formica F, D'Alessandro S, Singh G, et al. The impact of the radial artery or the saphenous vein in addition to the bilateral internal mammary arteries on late survival: A propensity score analysis. J Thorac Cardiovasc Surg. 2019;158:141-151. 29) Pevni D, Mohr R, Kramer A, Paz Y, Nesher N, Ben-Gal Y. Are two internal thoracic grafts better than one? An analysis of 5301 cases. Eur J Cardiothorac Surg. 2019;56:935-941. Franziska H, Fred R. Management of Acute Ischemic Stroke. Critical Care Medicine, 2020;48:1654-1663. 30) Laudani C, Greco A, Occhipinti G, Ingala S, Calderone D, Scalia S, et al. Short Duration of DAPT Versus De-Escalation After Percutaneous Coronary Intervention for Acute Coronary Syndromes. J Am Coll Cardiol Intv. 2022;3:268–277. 31) Angiolillo DJ, Galli M, Collet JP, Kastrati A, O'Donoghue ML, Antiplatelet therapy after percutaneous coronary intervention. EuroIntervention 2022;17:e1371-e1396.

Supplementary material

Table S1. Algorithm literature search

Search	PUBMED	
#1	(("coronary artery bypass"[Title/Abstract] OR	23,119
	"cabg"[Title/Abstract]) AND 2010/01/01:2023/01/31[Date -	
	Publication]) AND (2010/1/1:2023/1/31[pdat])	
#2	(("drug eluting stent"[Title/Abstract] OR	
	"des"[Title/Abstract] OR "stenting"[Title/Abstract]) AND	
	2010/01/01:2023/01/31[Date - Publication]) AND	
	(2010/1/1:2023/1/31[pdat])	41,772
	(("percutaneous coronary intervention"[Title/Abstract] OR	
	"pci"[Title/Abstract]) AND 2010/01/01:2023/01/31[Date -	
#3	Publication]) AND (2010/1/1:2023/1/31[pdat])	40,603
	(("left main disease"[Title/Abstract] OR "left main coronary	
	artery disease"[Title/Abstract]) AND	
	2010/01/01:2023/01/31[Date - Publication]) AND	
#4	(2010/1/1:2023/1/31[pdat])	1,227
	("multivessel coronary artery disease"[Title/Abstract] AND	
	2010/01/01:2023/01/31[Date - Publication]) AND	
#5	(2010/1/1:2023/1/31[pdat])	914
#6	#1 AND #2 AND #3 AND #4 OR #5	1064
	("randomised"[Title/Abstract] OR	
	"randomized"[Title/Abstract] OR "trial"[Title/Abstract])	
#7	AND (2010/1/1:2023/1/31[pdat])	737,198
	("long term follow up"[Title/Abstract] OR "extended follow	
#8	up"[Title/Abstract]) AND (2010/1/1:2023/1/31[pdat])	39,605
#9	#7 AND #8	6,339
#10	#6 AND #9	27
	EMBASE	
	('coronary artery bypass' OR 'cabg':ab,ti) AND [2010-	
#1	2023]/py	67,901
	('drug-eluting stent' OR 'des' OR 'stenting':ti,ab) AND	
#2	[2010-2023]/py	373,598

	('percutaneous coronary intervention' OR 'pci':ti,ab)	
#3	AND [2010-2023]/py	108,182
	('left main disease' OR 'left main coronary artery	
#4	disease':ti,ab) AND [2010-2023]/py	2,511
	'multivessel coronary artery disease':ti,ab AND [2010-	
#5	2023]/py	1,624
	(randomized OR randomised OR trial:ab,ti) AND [2010-	
#6	2023]/py	1,388,705
#7	#1 AND #2 AND #3 AND #4	449
	('long term follow-up' OR 'extended follow-up' AND	
#8	[2010-2023]/py	71,382
#9	#6 AND #7 AND #8	72
	CENTRAL	
	(left main disease):ti,ab,kw OR (left main coronary artery	
	disease):ti,ab,kw (Word variations have been searched) with	
#1	Publication Year from 2010 to 2023, in Trials	1747
	(multivessel coronary artery disease):ti,ab,kw with	
	Publication Year from 2010 to 2023, in Trials (Word	
#2	variations have been searched)	189
	(percutaneous coronary intervention):ti,ab,kw OR	
	("PCI"):ti,ab,kw (Word variations have been searched) with	
#3	Publication Year from 2010 to 2023, in Trials	11849
	("drug eluting stent"):ti,ab,kw OR (des):ti,ab,kw OR	
	(stenting):ti,ab,kw with Publication Year from 2010 to 2023,	
#4	in Trials (Word variations have been searched)	13973
	("coronary artery bypass"):ti,ab,kw OR (cabg):ti,ab,kw with	
	Publication Year from 2010 to 2023, in Trials (Word	
#5	variations have been searched)	7608
	(randomized):ti,ab,kw OR (trial):ti,ab,kw OR	
	(randomised):ti,ab,kw with Publication Year from 2010 to	
#6	2023, in Trials (Word variations have been searched)	902056
#7	#1 AND #3 AND #4 AND #5	226
#8	#7 OR #2	410
#9	#8 AND #6	376

Table S2. Risk of bias assessment using the Cochrane Collaboration revised tool for randomized control trials (RoB 2)

Study	<u>D1</u>	<u>D2</u>	<u>D3</u>	<u>D4</u>	<u>D5</u>	<u>Overall</u>
FREEDOM 2012	Low risk					
SYNTAX 2013	Low risk					
PRECOMBAT 2015	Low risk					
BEST 2015	Low risk					
EXCEL 2019	Low risk					
NOBLE 2020	Low risk					

Low risk Some concerns High risk

D1 Randomisation process

Deviations from the intended

D2 interventions

658 659

660

684


D3 Missing outcome data

Measurement of the outcome D4

Selection of the reported result D5

Fig. S1. The PRISMA Flow Chart of study selection process





698 Table S3. Endpoint definition of single trials 699 700 Trial Enrollment Periods and Inclusion and Exclusion Criteria 701 702 **SYNTAX** 703 704 Study Period: from March 2005 to April 2007 705 85 centres (Europe and USA) adhered to the SYNTAX protocol 706 707 Main inclusion criteria: 708 Three vessel disease or left main disease (>50% stenosis or left main equivalent) 709 No previous CABG or PCI 710 o Patients with stable or unstable angina or with evidence of documental ischemia if 711 asymptomatic o Decision by local Heart Team (cardiac surgeon and interventional cardiologist) that either 712 713 CABG or PCI can realize equivalent anatomical revascularization. 714 715 716 **PRECOMBAT** 717 Study Period: from April 2004 to August 2009 718 719 13 centers in South Korea adhered to the PRECOMBAT protocol 720 Main inclusion criteria: 721 722 723 diagnosis of stable angina, unstable angina, silent ischemia, or non-ST-segment elevation my ocardial infarction; 724 725 o new diagnosis of unprotected left main coronary artery (ULMCA) stenosis (>50% by 726 angiographic visual estimation); 727 patients were considered by local Heart Team (cardiac surgeon and interventional 728 cardiologist) to be a suitable candidate for either PCI or CABG. 729 730 Main exclusion criteria: 731 732 contraindication to any of the following medications: Heparin, Aspirin, Both clopidogrel and ticlo All rights reserved. No reuse allowed without permission.

pidine, Sirolimus, Stainless steel and/or Contrast media; 733 734 any previous percutaneous coronary intervention (PCI) of a ULMCA or ostial left circumflex arte ry or ostial left anterior descending artery within 1 year or previous CABG; 735 736 acute MI within 1 week; 737 ejection fraction <30%; 738 cardiogenic shock; 739 any stroke or any cerebrovascular accident within 6 months Creatinine level ≥ 2.0 mg/dL or dependence on dialysis. 740 741 Severe hepatic dysfunction 742 **BEST** 743 Study Period: from July 2008 – to September 2013 744 745 746 27 sites in South Korea, China, Malaysia, and Thailand adhered to the BEST protocol 747 748 Main key inclusion criteria: 749 ○ Age \ge 18 years. o Angiographically confirmed multivessel CAD (stenosis > 70%) in at least 2 major epicardial 750 751 vessels (≥ 2.0 mm in diameter) in at least two separate coronary artery territories (LAD, LCX 752 , RCA) and valuated to be equally managed with PCI or CABG). 753 Indication for intervention based on symptoms of angina and/or evidence of myocardial ische 754 mia. 755 Agreement by the patient or guardian to the study protocol and the clinical follow-up. Provision of written informed consent. 756 757 Main key exclusion criteria: 758 Known hypersensitivity or contraindication to any of: Heparin, Aspirin, Clopidogrel, Everoli 759 mus Stainless steel and/or true anaphylaxis to prior contrast media 760 Severe congestive heart failure. The left ventricular ejection fraction was not considered a crit 761 erion for exclusion. 762 Planned simultaneous surgical procedure (e.g., valve repair/replacement, aneurysmectomy, ca

763 rotid endarterectomy or carotid stent). 764 Previous CABG 765 Prior PCI with DES within 1 year. Two or more chronic total occlusions in major coronary territories. 766 767 Acute ST-elevation myocardial infarction within 72 hours prior to enrollment. 768 Abnormal creatine kinase (CK > 2× normal) and/or abnormal CK-MB levels and/or elevated t 769 roponin levels at the time of randomization. 770 Previous stroke within 6 months or stroke at more than 6 months with residual neurologic inv 771 olvement. 772 Extra-cardiac disease with life expectancy less than 2 years, e.g., COPD, active hepatitis, hep atic failure, or severe renal disease. 773 Prior history of significant bleeding 774 775 Contraindication to either CABG or PCI/DES due to a coexisting clinical condition. Intolerance or contraindication to aspirin or clopidogrel. 776 777 Suspected pregnancy. 778 Concurrent enrollment in another clinical trial. 779 Left main coronary artery stenosis (> 50% diameter). 780 781 **FREEDOM** 782 783 Study Period: from April 2005 – to April 2010 784 141 sites worldwide adhered to the FREEDOM protocol. 785 786 787 Main key inclusion criteria: 788 Patients with diabetes (Type 1 or Type 2) and angiographically confirmed multivessel coronary artery disease with stenosis of more than 70% in two or more major epicardial 789 790 vessels involving least two separate coronary-artery territories and without left main coronary 791 stenosis.

792 multivessel disease suitable for either approach 793 Indication for revascularization based upon symptoms of angina and/or objective evidence of 794 myocardial ischemia 795 Willing to comply with all follow-up required study visits Signed and received copy of informed consent 796 797 798 Main key exclusion criteria: 799 Two or more chronic total occlusions in major coronary territories. 800 Abnormal creatine kinase (CK > 2x normal) level at coronary territories time of 801 randomization. Extra-cardiac illness with a life expectancy lower than 5 years 802 803 Severe congestive heart failure Prior CABG surgery 804 Prior cardiac valve surgery 805 Prior PCI with DES within 6 months 806 Previous stroke within 6 months or patients with stroke with significant residual neurologic 807 involvement 808 In-stent restenosis of target vessel 809 Left main stenosis (>50% diameter stenosis) 810 o Acute ST-elevation MI within 72 h before enrollment Planned simultaneous surgical procedure (eg, valve repair/replacement, aneurysmectomy, 811 carotid endarterectomy, or carotid stent) 812 813 Contraindication to either CABG or PCI/DES 814 Significant leukopenia, neutropenia, thrombocytopenia, anemia, or known bleeding diathesis Intolerance or contraindication to aspirin or both clopidogrel and ticlopidine. 815 816 Dementia 817 Suspected pregnancy 818 Geographically inaccessible for follow-up visits required by protocol 819 820 821 822 823 824 825 826 827 828 829 830 831

Table S4. Restricted Mean Survival Time (RMST)

RMST	CABG	PCI	RMST difference	p-value
5-years	4.71 (95% CI, 4.67-	4.64 (95% CI,	0.07 years (25 days) (95%	p=0.02
	4.75) years	4.60-4.68) years	CI, 0.01-0.125;)	
8-years	7.16 (95% CI, 7.08-	7.30 (95% CI,	0.14 years (1.7 months)	p=0.009
	7.24) years	7.23-7.38) years	(95% CI, 0.03-0.25;)	
10-years	8.93 (95% CI, 8.83-	8.73 (95% CI,	0.20 years (95% CI, 0.05-	p=0.007
	9.03) years	8.62-8.84) years	0.35;)	

Fig. S2, S3, S4. ALL-CAUSE MORTALITY.

882




Fig. S2. Log-minus-log survival curves Predicted versus observed survival functions




Fig. S4. Scaled Schoenfeld residuals

Fig. S5. Time-to-event reconstructed curves for repeat coronary revascularization




Fig. S6. Time-to-event reconstructed curves for composite endpoints of all-cause mortality, myocardial infarction or stroke

